These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17020686)

  • 1. [Review of the scientific evidence of the efficiency of erythropoietin use].
    García-Altés A; Puig-Junoy J
    Med Clin (Barc); 2006 Sep; 127(11):415-20. PubMed ID: 17020686
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of recombinant erythropoietin in the treatment of anemia of chronic renal insufficiency].
    Drüeke T; Zins B; Bererhi L; Casadevall N; Varet B
    Presse Med; 1989 Jun; 18(25):1235-7. PubMed ID: 2525772
    [No Abstract]   [Full Text] [Related]  

  • 3. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 4. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 5. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 6. Neocytolysis: from outer space to the dialysis unit.
    Means RT
    Am J Kidney Dis; 1999 Jan; 33(1):140-1. PubMed ID: 9915281
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
    Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
    Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
    [No Abstract]   [Full Text] [Related]  

  • 8. Hemoglobin normalization studies.
    Reddan D; Lappin DW; Tierney M; Szczech LA
    Perit Dial Int; 2007; 27(4):395-9. PubMed ID: 17602145
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 10. Erythropoiesis-stimulating agents in kidney and cardiac disease.
    Fluck R
    Br J Hosp Med (Lond); 2006 Oct; 67(10):533-7. PubMed ID: 17069130
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. Results of a multicenter phase II/III study.
    Pollok M; Bommer J; Gurland HJ; Koch KM; Schoeppe W; Scigalla P; Baldamus CA
    Contrib Nephrol; 1989; 76():201-11; discussion 212-8. PubMed ID: 2684523
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathogenesis of uremic anemia and new therapeutic prospectives.
    Lamperi S; Carozzi S; Icardi A; Nasini MG; Traverso GB
    Contrib Nephrol; 1989; 69():190-4; discussion 195-6. PubMed ID: 2661141
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of the anaemia of chronic renal failure with recombinant erythropoietin.
    Adamson JW; Eschbach JW
    Q J Med; 1989 Dec; 73(272):1093-101. PubMed ID: 2694210
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 15. [Variability of the hemoglobin level: each patient is unique].
    Zaoui P; Deray G; Ortiz JP; Rostaing L
    Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H1-4. PubMed ID: 21371677
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to recombinant human erythropoietin (rHu-Epo) in a patient with chronic renal failure and myelomonocytic leukaemia.
    Salvati F; Liani M; Bonomini M
    Nephrol Dial Transplant; 2001 Jan; 16(1):191-2. PubMed ID: 11209030
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO.
    Suzuki M; Hirasawa Y; Hirashima K; Arakawa M; Odaka M; Ogura Y; Yoshikawa Y; Sanaka T; Shinoda A; Morii H
    Contrib Nephrol; 1989; 76():179-92; discussion 212-8. PubMed ID: 2684520
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin for anemia.
    Med Lett Drugs Ther; 1989 Sep; 31(801):85-6. PubMed ID: 2671624
    [No Abstract]   [Full Text] [Related]  

  • 19. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.".
    Belonje AM; de Boer RA; Voors AA
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):1-2. PubMed ID: 18219567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.